But this comes in second-line breast cancer, a use the group isn’t pursuing.
ApexOnco Front Page
Recent articles
The company admits defeat with zelenectide.
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
Claudin18.2 is out, but the US big pharma opts in to a new project.
The company sticks with EZH2, despite others adding EZH1 inhibition.
Questions continue to swirl as the unit mulls another oncology makeover.
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.